Skip to main content

Table 1 Baseline demographics in the total vaccinated cohort

From: Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

 

Infants

Children

Adults

 

6–35 months

3–17 years

18–49 years

 

IIV4-I N = 466

IIV4 N = 474

IIV4-I N = 410

IIV4 N = 411

IIV4-I N = 60

IIV4 N = 60

Mean age, (SD)

19.7 (8.0) months

19.9 (8.3) months

9.4 (4.2) years

9.4 (4.2) years

29.8 (8.7) years

31.2 (9.3) years

Median age, (range)

19 (4–36) months

19 (5–35) months

9.0 (3–18) years

10.0 (3–18) years

28.0 (19–49) years

29.0 (18–49) years

Male, n (%)

243 (52.1)

265 (55.9)

214 (52.1)

224 (54.5)

19 (31.7)

25 (41.7)

White - Caucasian/European Heritage, n (%)

329 (70.6)

337 (71.1)

378 (92.2)

370 (90.0)

60 (100)

56 (93.3)

African Heritage/African American, n (%)

10(2.1)

10 (2.1)

11 (2.7)

17 (4.1)

0

2 (3.3)

Asian - South East Asian Heritage, n (%)

91 (19.5)

91 (19.2)

0

0

0

2 (3.3)

White - Arabic/North African Heritage, n (%)

28 (6.0)

23 (4.9)

13 (3.2)

15 (3.6)

0

0

  1. IIV4-I quadrivalent inactivated influenza vaccine manufacturing by investigational process, IIV4 licensed quadrivalent inactivated influenza vaccine, SD standard deviation, N number of subjects with ≥1 vaccine dose, n number of subjects fulfilling the demographic